A First-of-Its-Kind Drug Could Change How Scientists Fight Prostate Cancer
Reported bySciTechDaily ↗·Sourced by Goodlede
Bavdegalutamide (ARV-110), a first PROTAC androgen receptor degrader, reduced tumor activity and pain in a Phase I/II clinical trial of men with metastatic castration-resistant prostate cancer, with greater responses in patients carrying specific androgen receptor mutations.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at SciTechDaily
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Health
Health Canada approves first functional cure for some chronic hepatitis B patients
CBC Health · Verified
Animals
Belize secures final link in critical wildlife corridor connecting Mesoamerica's largest forest block
Re:wild · Verified
Animals
Grad student finds New Mexico's first Canada lynx in 25 years
Popular Science · Verified